Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hutchmed China Ltd ADR
(NQ:
HCM
)
20.17
-0.79 (-3.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Hutchmed China Ltd ADR
< Previous
1
2
3
Next >
HUTCHMED to Announce 2023 Half-Year Financial Results
June 26, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
June 15, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
June 15, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
June 09, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
May 25, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
May 25, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
May 18, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces Board of Directors and Board Committee Membership
May 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
May 15, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
May 10, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
May 09, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
April 17, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
April 11, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Intended Retirement of Independent Non-executive Director
April 11, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
April 04, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
March 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
February 28, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
February 27, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2022 Final Results
January 31, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
January 23, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
January 18, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
January 03, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
December 19, 2022
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
December 16, 2022
From
Prenetics Limited
Via
GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for On-Demand Viewing
November 18, 2022
Company Executives Shared Vision and Answered Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
November 14, 2022
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
November 13, 2022
From
HUTCHMED (China) Limited
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2022
November 09, 2022
From
Virtual Investor Conferences
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.